Literature DB >> 11280795

The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.

B K Linderholm1, T Lindahl, L Holmberg, S Klaar, J Lennerstrand, R Henriksson, J Bergh.   

Abstract

Wild-type p53 protein has been shown to inhibit angiogenesis through thrombospondin in the preclinical setting. Here, we determined the associations between the expression of the angiogenic factor vascular endothelial growth factor (VEGF) and the p53 status, including different mutation sites and types, in primary breast cancer. Cytosols from 224 primary breast cancer patients were analyzed with an enzyme immunoassay for determination of human VEGF165 protein content. p53 status was determined by cDNA-based sequencing of the entire coding region, by immunohistochemistry (IHC), and by a p53 luminometric immunoassay (LIA) method. Statistically significant associations was found between higher VEGF content and non-wild-type p53 status for all methods; sequence-based data (P = 0.0019), IHC data (P = 0.0068), and the LIA method (r = 0.427; P > 0.001). Highest VEGF values were detected in tumors with p53 insertions, deletions, and stop codon mutations (P = 0.0043). Combining p53 status and VEGF content resulted in additional prognostic information, relapse-free survival (RFS; P = 0.0377), overall survival (OS; P = 0.0319), and breast cancer corrected survival (BCCS; P = 0.0292). In multivariate analysis, the relative hazard increased when the VEGF data were added to the p53 status, with a relative hazard of 1.7 for RFS and 3.0 for BCCS, compared with 1.1 for RFS and 1.4 for BCCS among the patients with either high VEGF content or p53 mutation. Higher VEGF content was statistically significantly correlated with a worse outcome for patients with estrogen receptor-positive tumors receiving adjuvant tamoxifen: RFS (P = 0.0471), OS (P = 0.0134), BCCS (P = 0.0064), as well as in multivariate analysis with point estimates of 3.4 and 2.1 for BCCS and RFS, respectively. VEGF expression is related to p53 status in human breast cancer patients. Combining VEGF with p53 status resulted in better prognostic prediction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280795

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  How do I treat "triple-negative" disease.

Authors:  Christos Vaklavas; Andres Forero-Torres
Journal:  Curr Treat Options Oncol       Date:  2011-12

2.  Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.

Authors:  Stylianos Drisis; Thierry Metens; Michael Ignatiadis; Konstantinos Stathopoulos; Shih-Li Chao; Marc Lemort
Journal:  Eur Radiol       Date:  2015-08-27       Impact factor: 5.315

Review 3.  Context is everything: extrinsic signalling and gain-of-function p53 mutants.

Authors:  Ivano Amelio; Gerry Melino
Journal:  Cell Death Discov       Date:  2020-03-23

Review 4.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

5.  Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival.

Authors:  LaCreis R Kidd; Guy N Brock; Tiva T VanCleave; Marnita L Benford; Nicole A Lavender; Traci L Kruer; James L Wittliff
Journal:  Cancer Causes Control       Date:  2010-06-23       Impact factor: 2.506

Review 6.  Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.

Authors:  Daniel J Toft; Vincent L Cryns
Journal:  Mol Endocrinol       Date:  2010-09-22

7.  Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma.

Authors:  L Maggiorella; C Aubel; C Haton; F Milliat; E Connault; P Opolon; E Deutsch; J Bourhis
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

8.  Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer.

Authors:  Hayra de Andrade Vieira-Monteiro; Daniely Regina Freitas-Alves; Marcelo Sobral-Leite; João Marcos de Azevedo Delou; Sheyla Maria Torres Goulart-Citrangulo; Camila Telles do Nascimento; Thales Nascimento E Castro; Sérgio Koifman; Jamila Alessandra Perini; Rosane Vianna-Jorge
Journal:  Cancer Biol Ther       Date:  2016-06-02       Impact factor: 4.742

Review 9.  p53 gene therapy for esophageal cancer.

Authors:  Hideaki Shimada; Hisahiro Matsubara; Takenori Ochiai
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

10.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Authors:  Giulia Fontemaggi; Stefania Dell'Orso; Daniela Trisciuoglio; Tal Shay; Elisa Melucci; Francesco Fazi; Irene Terrenato; Marcella Mottolese; Paola Muti; Eytan Domany; Donatella Del Bufalo; Sabrina Strano; Giovanni Blandino
Journal:  Nat Struct Mol Biol       Date:  2009-09-27       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.